CN110448551A - 二氢青蒿素衍生物在制备抗血管生成药物中的应用 - Google Patents
二氢青蒿素衍生物在制备抗血管生成药物中的应用 Download PDFInfo
- Publication number
- CN110448551A CN110448551A CN201910785570.9A CN201910785570A CN110448551A CN 110448551 A CN110448551 A CN 110448551A CN 201910785570 A CN201910785570 A CN 201910785570A CN 110448551 A CN110448551 A CN 110448551A
- Authority
- CN
- China
- Prior art keywords
- cdcl
- alkyl
- nmr
- independently
- 300mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 230000001772 anti-angiogenic effect Effects 0.000 title claims description 8
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 title claims description 7
- 229960002521 artenimol Drugs 0.000 title claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- -1 amino, hydroxyl Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001924 fatty-acyl group Chemical group 0.000 claims 1
- 150000000138 dihydroartemisinin derivatives Chemical class 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000003527 anti-angiogenesis Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 94
- 238000004896 high resolution mass spectrometry Methods 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000002002 slurry Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 3
- 229960004191 artemisinin Drugs 0.000 description 3
- 229930101531 artemisinin Natural products 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229930016266 dihydroartemisinin Natural products 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- AAPRNHKWNGDTOT-DVRVPOOOSA-N 2-[(3s)-3-(aminomethyl)piperidine-1-carbonyl]-n-[1-(cyclononen-1-ylmethyl)piperidin-4-yl]-9h-xanthene-9-carboxamide Chemical compound C1[C@H](CN)CCCN1C(=O)C1=CC=C(OC=2C(=CC=CC=2)C2C(=O)NC3CCN(CC=4CCCCCCCC=4)CC3)C2=C1 AAPRNHKWNGDTOT-DVRVPOOOSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- TYOWVJZFGQJLMZ-UHFFFAOYSA-N 2h-benzotriazole;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=C2NN=NC2=C1 TYOWVJZFGQJLMZ-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WZUUZPAYWFIBDF-UHFFFAOYSA-N 5-amino-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound NC1=NNC(S)=N1 WZUUZPAYWFIBDF-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- ZBXNFTFKKOSPLD-UHFFFAOYSA-N 5-methylsulfanyl-2h-tetrazole Chemical compound CSC1=NN=NN1 ZBXNFTFKKOSPLD-UHFFFAOYSA-N 0.000 description 1
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 150000007980 azole derivatives Chemical class 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000000524 functional group Chemical class 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了式I所示的二氢青蒿素衍生物在制备抗血管生成药物中的应用，拓宽了二氢青蒿素衍生物的制药用途。
Description
技术领域
本发明属于化合物的医药用途技术领域，涉及一类二氢青蒿素衍生物在制备抗血管生成的药物中的应用。
背景技术
青蒿素及其衍生物具有高效、快速和低毒的抗疟活性，在全世界范围内得到广泛应用。近年来研究表明，青蒿素及其衍生物还具有抗炎、抗细菌脓毒症、抗组织纤维化和抗肿瘤等多种生物活性。目前对青蒿素的研究主要集中在提高活性、拓宽药效、增加稳定性和溶解性等方面。发明人所在课题组在过去的研究中，将一些活性小分子或药物引入到二氢青蒿素结构中，设计了多种结构类型的二氢青蒿素衍生物，通过条件的探索，简易、高收率地实现了这些目标化合物的合成，并发现其中部分化合物虽然本身不具备抗菌作用，但其可以作为β-内酰胺类抗生素的抗菌增效剂。
在多种疾病的发病机制中均涉及到血管生成，包括实体瘤、眼内新生血管综合征如增殖性视网膜病变和年龄相关性黄斑变性等。与正常的组织细胞相比，在实体肿瘤中，新血管的生成能够使肿瘤细胞获得生长优势和自主增殖能力。同时，研究发现肿瘤切片中微血管密度与患者生存率之间存在一定联系。血管内皮生长因子(VEGF)在正常的血管生成以及肿瘤和眼科疾病相关的异常血管生成中均起着重要的调节作用。对VEGF信号通路的抑制可限制多种肿瘤的进展以及其他以血管异常增生为特点的并发症的发生与发展。
发明内容
本发明的目的在于考察二氢青蒿素衍生物在抗血管生成方面的活性，以拓宽二氢青蒿素衍生物的制药用途。
经研究，本发明提供如下技术方案：
1.式I所示的二氢青蒿素衍生物或其消旋体、立体异构体、互变异构体、氮氧化物、药学上可接受的盐在制备抗血管生成药物中的应用：
式I中，n为1或2；
Y为-NR1R2、
R1和R2独立地为H、C1-C3烷基或C1-C3羟烷基；
R3为H、C1-C3烷基、C1-C3羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或脂肪酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基；
R4和R5独立地为H或C1-C3烷基；
R6和R7独立地为H、氨基、羟基或C1-C3烷基；
R8为H、C1-C3烷基、C1-C3烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基。
进一步，式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或烷酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基。
进一步，式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、苯基、叔丁氧羰基、苄氧羰基或乙酰基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基或苯基。
进一步，式I中，
R1和R2独立地为H、甲基、乙基或羟乙基；
R3为H、甲基、羟乙基、苯基或叔丁氧羰基；
R4和R5独立地为H或甲基；
R6和R7独立地为H或氨基；
R8为H、甲基、甲硫基或苯基。
进一步，式I所示的二氢青蒿素衍生物为以下化合物中的任一种：
进一步，式I所示的二氢青蒿素衍生物为以下化合物中的任一种：1c,2a-4,2a-5,2b-1,4b-6,4b-8,5b-6。
除另有说明外，本发明中的术语“消旋体”是指由等量对映体构成的光学不活性的有机物。“立体异构体”是指原子组成及键接相同而原子在三维空间排列上不同的分子。“互变异构体”是指因分子中某一原子在两个位置迅速移动而产生的官能团异构体。“氮氧化物”是指三级氮连接氧原子形成+N-O-结构单元的有机物。“药学上可接受的盐”可以是酸性盐，也可以是碱性盐，例如无机酸盐、有机酸盐、无机碱盐或有机碱盐。
本发明的有益效果在于：本发明公开了式I所示的二氢青蒿素衍生物在制备抗血管生成的药物中的应用，拓宽了二氢青蒿素衍生物的制药用途。
具体实施方式
为了使本发明的目的、技术方案和有益效果更加清楚，下面将对本发明的优选实施例进行详细的描述。
优选实施例中使用的主要试剂及规格:二甲胺、二乙胺、乙醇胺、氮甲基乙醇胺、二乙醇胺、吡咯烷、哌啶、吗啉、乙腈、二氯甲烷(重庆化学试剂总厂,AR)；无水哌嗪、N-甲基哌嗪、N-羟乙基哌嗪、N-Boc-哌嗪、N-苯基哌嗪、3-溴-1-丙醇、咪唑、2-甲基咪唑、4-甲基咪唑、吡唑、3,5-二甲基吡唑、苯并咪唑、1,2,3-三氮唑、1,2,4-三氮唑、苯并三氮唑、3-氨基-1,2,4-三氮唑、3-氨基-5-巯基-1,2,4-三氮唑、1-H-四氮唑、5-甲基四氮唑、5-苯基四氮唑、5-甲巯基四氮唑(上海达瑞精细化工有限公司,＞98％)；1-羟基-苯并三氮唑(上海共价化学科技公司,工业级)；二氢青蒿素(重庆华立武陵山制药有限公司,AR)；溴乙醇(上海达瑞精细化工有限公司,AR)；46.5％BF3.Et2O(上海晶纯试剂有限公司,AR)；其余试剂均为市售化学纯或分析纯产品,未经纯化直接使用。
优选实施例中使用的主要仪器及型号:精密显微熔点测定仪(X-6,北京福凯仪器有限公司)；数字式自动旋光仪(WZZ-2S,上海精密科学仪器有限公司)；超导核磁共振波谱仪(AV-300,Bruker,瑞士)；高分辨质谱仪(HR ESI MS)(Varian7.0T,Varian,USA)。
实施例1、DHA胺类衍生物的合成
1、DHA脂肪胺类衍生物1的合成
DHA脂肪胺类衍生物1a-1h按照文献(Chong Wu,et al.Design,Synthesis andEvaluation of the Antibacterial Enhancement Activities of AminoDihydroartemisinin Derivatives.Molecules,2013,18,6866-6882)中所述化合物4a-4u的制备方法进行制备。
2、DHA哌嗪类衍生物2的合成
1)中间体M1的合成
中间体M1按照中国专利104418864B(双氢青蒿素与喹诺酮类化合物的偶联物及其制备方法和应用)中所述中间体IM1和IM2的制备方法进行制备。
2)DHA哌嗪类衍生物2a-1～2a-5及2b-1～2b-5的合成
在100mL圆底烧瓶中依次加入M1、CH3CN、K2CO3及哌嗪或取代哌嗪,控温搅拌反应,TLC监测反应进程。反应结束后,加入CH2Cl2 15mL和饱和NaCl水溶液20mL,静置分层,水层用CH2Cl2(10mL×2)萃取,合并有机相,饱和食盐水20mL洗涤,无水Na2SO4干燥,减压旋蒸除去CH2Cl2得粗品或纯品,必要时柱层析,干燥,即得目标化合物2。具体合成条件及结果见表1。
表1目标化合物2的合成条件及结果
目标化合物2表征数据如下:
2a-1:1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝6.6Hz,H-14),1.43(3H,s,H-15),1.22-2.06(10H,m,H-2,H-3,H-7～H-10),2.37-2.60(12H,m,H-1,H-11,H-17～H-19),3.52-3.59(1H,m,H-16),3.91-3.98(1H,m,H-16),4.80(1H,s,H-12),5.45(1H,s,H-5).
2a-2:1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-13),0.96(3H,d,J＝6.6Hz,H-14),1.43(3H,s,H-15),1.46(9H,s,H-22),1.22-2.06(10H,m,H-2,H-3,H-7～H-10),2.30(3H,s,H-20),2.37-2.60(12H,m,H-1,H-11,H-17～H-19),3.52-3.59(1H,m,H-16),3.91-3.98(1H,m,H-16),4.80(1H,s,H-12),5.45(1H,s,H-5).
2a-3:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.3Hz,H-13),0.95(3H,d,J＝6.0Hz,H-14),1.42(3H,s,H-15),1.15-2.06(10H,m,H-2,H-3,H-7～H-10),2.28-2.59(14H,m,H-1,H-11,H-17～H-20),3.36-4.43(1H,m,H-16),3.62(2H,t,J＝5.3Hz,H-21),3.84-3.91(1H,m,H-16),4.77(1H,d,J＝3.3Hz,H-12),5.30(1H,s,H-22),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:103.98(C-4),101.90(C-12),87.84(C-5),81.07(C-6),68.54(C-16),59.36(C-22),57.72(C-20),55.52(C-17),53.26(C-19),52.45(C-1),46.76(C-18),44.31(C-7),37.39(C-11),36.32(C-10),34.57(C-3),30.76(C-9),26.12(C-8),24.63(C-15),24.30(C-2),20.29(C-14),13.01(C-13).HRMS:C23H40N2O6[M+H]+计算值441.2959,测定值441.2954.
2a-4:m.p.:107.8-109.1℃； 1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.2Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.43(3H,s,H-15),1.46(9H,s,H-22),1.22-2.06(10H,m,H-2,H-3,H-7～H-10),2.32-2.65(8H,m,H-1,H-11,H-17 and H-18),3.40-3.44(4H,m,H-19),3.52-3.58(1H,m,H-16),3.92-4.00(1H,m,H-16),4.80(1H,s,H-12),5.46(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.6(C-21),104.0(C-4),101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.0(C-16),57.9(C-17),53.5(C-19),52.0(C-1),49.2(C-18),44.4(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),28.4(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4(C-14),13.0(C-13).HR MS:C27H40N2O5[M+H]+计算值497.3221,测定值497.3222.
2a-5:m.p.:90.0-91.7℃； 1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.2Hz,H-13),0.95(3H,d,J＝6.0Hz,H-14),1.44(3H,s,H-15),1.23-2.06(10H,m,H-2,H-3,H-7～H-10),2.32-2.42(1H,m,H-1),2.59-2.70(7H,m,H-11,H-17 and H-18),3.21(4H,t,J＝7.5Hz,H-19),3.58-3.65(1H,m,H-16),3.98-4.05(1H,m,H-16),4.83(1H,d,J＝2.7Hz,H-12),5.48(1H,s,H-5),6.89(1H,t,J＝7.2Hz,H-23),6.94(2H,d,J＝7.8Hz,H-21),7.25-7.30(2H,m,H-22)；13C NMR(75MHz,CDCl3)δ:151.3(C-20),129.1(C-22),120.0(C-23),116.0(C-21),104.0(C-4),102.0(C-12),87.9(C-5),81.1(C-6),66.0(C-16),57.9(C-17),53.5(C-19),52.6(C-1),49.2(C-18),44.4(C-7),37.5(C-11),36.4(C-10),34.7(C-3),30.9(C-9),26.2(C-8),24.7(C-15),24.4(C-2),20.3(C-14),13.1(C-13).HR MS:C27H40N2O5(M+H)+计算值473.3010,测定值473.3014.
2b-1:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.2Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.44(3H,s,H-15),1.26-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37-2.62(12H,m,H-1,H-11,H-18～H-20),3.37-3.44(1H,m,H-16),3.84-3.92(1H,m,H-16),4.77(1H,s,H-12),5.39(1H,s,H-5).
2b-2:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.2Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.44(3H,s,H-15),1.26-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.30(3H,s,H-20),2.37-2.62(12H,m,H-1,H-11,H-18～H-20),3.37-3.44(1H,m,H-16),3.84-3.92(1H,m,H-16),4.77(1H,s,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.1(C-4),101.9(C-12),87.8(C-5),81.0(C-6),66.5(C-16),55.5(C-18),55.0(C-19),53.1(C-20),52.5(C-21),46.0(C-1),44.4(C-7),37.1(C-11),36.4(C-10),34.6(C-3),30.9(C-9),27.0(C-17),26.2(C-8),24.6(C-15),24.4(C-2),20.3(C-14),13.0(C-13).HR MS:C23H40N2O5[M+H]+计算值425.3010,测定值425.3010.
2b-3:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.3Hz,H-13),0.95(3H,d,J＝6.0Hz,H-14),1.42(3H,s,H-15),1.15-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.28-2.59(14H,m,H-1,H-11,H-17～H-20),3.36-3.43(1H,m,H-16),3.62(2H,t,J＝5.3Hz,H-21),3.84-3.91(1H,m,H-16),4.77(1H,d,J＝3.3Hz,H-12),5.30(1H,s,H-23),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.00(C-4),101.90(C-12),87.81(C-5),81.04(C-6),66.43(C-16),59.31(C-22),57.68(C-20),55.42(C-17),53.06(C-19),52.76(C-18),52.49(C-1),44.35(C-7),37.42(C-11),36.35(C-10),34.56(C-3),30.84(C-9),26.97(C-17),26.12(C-8),24.61(C-15),24.40(C-2),20.30(C-14),12.97(C-13).HR MS:C24H42N2O6[M+H]+计算值455.3116,测定值455.3115.
2b-4:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.43(3H,s,H-15),1.47(9H,s,H-23),1.26-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.32-2.43(1H,m,H-1),2.61-2.64(1H,m,H-11),3.40-3.46(11H,m,H-16,H-18～H-20),3.92-4.00(1H,m,H-16),4.19(2H,t,J＝6.3Hz,H-14),4.76(1H,s,H-12),5.37(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.6(C-21),104.0(C-4),101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.5(C-16),55.3(C-18),52.6(C-20),52.5(C-19),52.0(C-1),44.4(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),28.4(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4(C-14),13.0(C-13).HR MS:C27H46N2O7[M+H]+计算值511.3378,测定值511.3370.
2b-5:1H NMR(300MHz,CDCl3)δ:0.92(3H,d,J＝7.5Hz,H-13),0.96(3H,d,J＝5.7Hz,H-14),1.44(3H,s,H-15),1.23-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.32-2.42(1H,m,H-1),2.49-2.65(7H,m,H-11,H-18 and H-19),3.22-3.25(4H,m,H-20),3.40-3.48(1H,m,H-16),3.88-3.96(1H,m,H-16),4.80(1H,d,J＝2.4Hz,H-12),5.41(1H,s,H-5),6.87(1H,t,J＝7.2Hz,H-23),6.94(2H,d,J＝7.8Hz,H-21),7.25-7.30(2H,m,H-22)；13C NMR(75MHz,CDCl3)δ:151.2(C-21),129.1(C-23),119.7(C-24),116.0(C-22),104.0(C-4),102.0(C-12),87.9(C-5),81.1(C-6),66.5(C-16),55.6(C-18),53.2(C-20),52.6(C-1),49.1(C-19),44.4(C-7),37.5(C-11),36.4(C-10),34.6(C-3),30.9(C-9),28.4(C-17),26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HR MS:C28H42N2O5[M+H]+计算值487.3167,测定值487.3162.
实施例2、DHA唑类衍生物的合成
在100mL圆底烧瓶中依次加入唑类化合物YH、N,N-二甲基甲酰胺(DMF)和碱(NaH或K2CO3),搅拌15min后,加入M1,控温搅拌反应,TLC监测反应进程。反应完成后,加入乙酸乙酯(EtOAc)15mL和饱和NaCl水溶液20mL,静置分层,水层用EtOAc(10mL×2)萃取，合并有机相,饱和食盐水20mL洗涤,无水Na2SO4干燥,减压旋蒸除去EtOAc得粗品或纯品，必要时柱层析,干燥,即得目标化合物3,4,5。具体合成条件及结果见表2,3,4。
表2目标化合物3的合成条件及结果
表3目标化合物4的合成条件及结果
表4目标化合物5的合成条件及结果
目标化合物3-5的表征数据如下：
3a-1:m.p.:93.7-95.1℃； 1H NMR(300MHz,CDCl3)δ:0.80(3H,d,J＝7.4Hz,H-14),0.93(3H,d,J＝5.5Hz,H-13),1.42(3H,s,H-15),1.17-2.08(10H,m,H-2,H-3,H-7～H-10),2.34(1H,td,J＝14.0,3.9Hz,H-1),2.51-2.65(1H,m,H-11),3.68-3.81(1H,m,H-16),4.19-4.41(3H,m,H-16 and H-17),4.75(1H,d,J＝3.4Hz,H-12),5.13(1H,s,H-5),6.23(s,1H,H-19),7.42(1H,s,H-20),7.51(1H,s,H-20)；13CNMR(75MHz,CDCl3)δ:139.29(C-20),129.67(C-19),105.16(C-18),103.98(C-4),101.87(C-12),87.70(C-5),80.89(C-6),66.66(C-16),52.37(C-1),51.99(C-17),44.10(C-7),37.11(C-11),36.29(C-10),34.46(C-3),30.62(C-9),26.08(C-8),24.57(C-15),24.14(C-2),20.29(C-14),12.81(C-13).HR MS:C20H30N2O5(M+Na)+计算值401.2047,测定值401.2050.
3a-2:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.85(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝6.1Hz,H-13),1.44(3H,s,H-15),1.22-2.07(10H,m,H-2,H-3,H-7～H-10),2.32-2.38(1H,m,H-1),2.61-2.63(1H,m,H-11),3.62-3.68(1H,m,H-16),4.15-4.21(3H,m,H-16 and H-17),4.76(1H,s,H-12),5.11(1H,s,H-5),7.00(1H,s,H-19),7.09(1H,s,H-18),7.62(1H,s,H-20)；13C NMR(75MHz,CDCl3)δ:128.7(C-20),123.1(C-19),118.9(C-18),104.1(C-4),102.0(C-12),87.8(C-5),80.8(C-6),67.0(C-16),52.3(C-1),47.2(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),13.0(C-13).HR MS:C20H30N2O5(M+H)+计算值379.2228,测定值379.2221.
3a-3:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝6.9Hz,H-14),0.95(3H,d,J＝6.3Hz,H-13),1.45(3H,s,H-15),1.19-2.06(10H,m,H-2,H-3,H-7～H-10),2.12(3H,s,H-21),2.32-2.43(1H,m,H-1),2.59-2.66(1H,m,H-11),3.40-3.52(4H,m,H-16 and H-17),4.69(1H,d,J＝2.7Hz,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:127.8(C-18),127.2(C-20),118.8(C-19),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.7(C-21).HR MS:C21H32N2O5(M+H)+计算值393.2384,测定值393.2382.
3a-4:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.85(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.8Hz,H-13),1.43(3H,s,H-15),1.22-2.07(10H,m,H-2,H-3,H-7～H-10),2.29-2.34(1H,m,H-1),2.41(3H,s,H-21),2.61-2.63(1H,m,H-11),3.58-3.63(1H,m,H-16),3.99-4.16(3H,m,H-16 and H-17),4.76(1H,d,J＝3.3Hz,H-12),5.08(1H,s,H-5).6.88(1H,s,H-19),6.92(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:126.7(C-20 and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.9(C-21).HRMS:C21H32N2O5(M+H)+计算值393.2384,测定值393.2386.
3a-5:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.81(3H,d,J＝7.2Hz,H-14),0.87(3H,d,J＝6.3Hz,H-13),1.42(3H,s,H-15),1.26-2.08(10H,m,H-2,H-3,H-7～H-10),2.29-2.37(1H,m,H-1),2.21(3H,s,H-21),2.28(3H,s,H-22),2.51-2.59(1H,m,H-11),3.64-3.69(1H,m,H-16),4.12-4.28(3H,m,H-16 and H-17),4.75(1H,d,J＝2.7Hz,H-12),5.07(1H,s,H-5).5.86(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:147.4(C-20),139.4(C-19),104.6(C-4),103.9(C-19),101.7(C-12),87.6(C-5),80.9(C-6),66.4(C-16),52.3(C-1),47.9(C-17),44.2(C-7),37.0(C-11),36.3(C-10),34.6(C-3),30.7(C-9),26.1(C-8),24.5(C-15),24.0(C-2),20.2(C-14),13.0(C-13),12.8(C-21),11.1(C-22)；HR MS:C22H34N2O5(M+Na)+计算值429.2360,测定值429.2356.
3a-6:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.76(3H,d,J＝7.5Hz,H-14),0.83(3H,d,J＝6.0Hz,H-13),1.39(3H,s,H-15),1.15-1.99(10H,m,H-2,H-3,H-7～H-10),2.24-2.35(H,m,H-1),2.52-2.59(H,m,H-11),3.70-3.76(1H,m,H-16),4.28-4.43(3H,m,H-16 and H-17),4.73(1H,d,J＝2.7Hz,H-12),4.91(1H,s,H-5),7.30(2H,t,J＝2.4Hz,H-21 and H-22),7.42(1H,d,J＝7.5Hz,H-23),7.80(1H,d,J＝7.5Hz,H-20),7.95(1H,s,H-18).
3b-1:m.p.:109.3-110.2℃； 1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝6.9Hz,H-14),0.96(3H,d,J＝5.6Hz,H-13),1.44(3H,s,H-15),1.17-2.22(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37(1H,m,H-1),2.59-2.72(1H,m,H-11),3.28-3.36(1H,m,H-16),3.82-3.89(1H,m,H-16),4.23(2H,t,J＝7.0Hz,H-18),4.78(1H,d,J＝3.3Hz,H-12),5.40(1H,s,H-5),6.25(1H,s,H-20),7.37(1H,s,H-19),7.52(1H,s,H-21)；13C NMR(75MHz,CDCl3)δ:139.31(C-21),129.09(C-20),105.25(C-19),104.06(C-4),102.01(C-12),87.84(C-5),81.00(C-6),64.96(C-16),52.47(C-1),49.00,44.29(C-7),37.38(C-11),36.33(C-10),34.54(C-3),30.82(C-17),30.49(C-9),26.13(C-8),24.62(C-15),24.46(C-2),20.33(C-14),13.09(C-13).HR MS:C21H32N2O5(M+Na)+计算值415.2203,测定值415.2202.
3b-2:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.94-0.98(6H,m,H-13 and H-14),1.43(3H,s,H-15),1.25-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.33-2.42(1H,m,H-1),2.60-2.71(1H,m,H-11),3.33-3.40(1H,m,H-16),3.83-3.90(1H,m,H-16),4.04(2H,t,J＝7.2Hz,H-18),4.78(1H,s,H-12),5.37(1H,s,H-5),6.91(1H,s,H-20),7.07(1H,s,H-19),7.47(1H,s,H-21)；13C NMR(75MHz,CDCl3)δ:137.1(21),129.5(C-20),118.8(C-19),104.1(C-4),102.0(C-12),87.9(C-5),80.9(C-6),64.4(C-16),52.5(C-1),44.2(C-7),43.8(C-18),37.5(C-11),36.3(C-10),34.5(C-3),31.2(C-17),30.8(C-9),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:C21H32N2O5[M+H]+计算值393.2384,测定值393.2386.
3b-3:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝6.9Hz,H-14),0.95(3H,d,J＝6.3Hz,H-13),1.45(3H,s,H-15),1.19-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.13(3H,s,H-22),2.32-2.43(1H,m,H-1),2.59-2.66(1H,m,H-11),3.40-3.52(4H,m,H-16 and H-18),4.69(1H,d,J＝2.7Hz,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:127.9(C-19),127.2(C-21),118.9(C-20),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-18),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),29.7(C-17),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.7(C-21).HR MS:C22H34N2O5[M+H]+计算值407.2540,测定值407.2542.
3b-4:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.85(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.8Hz,H-13),1.43(3H,s,H-15),1.22-2.07(12H,m,H-2,H-3,H-7～H-10 and H-17),2.29-2.34(1H,m,H-1),2.41(3H,s,H-21),2.61-2.63(1H,m,H-11),3.58-3.63(1H,m,H-16),3.99-4.16(3H,m,H-16 and H-17),4.76(1H,d,J＝3.3Hz,H-12),5.08(1H,s,H-5).6.88(1H,s,H-20),6.92(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:126.7(C-20 and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),29.6(C-17),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.9(C-21).HR MS:C22H34N2O5[M+H]+计算值407.2540,测定值407.2537.
3b-5:黄色油状物； 1H NMR(400MHz,CDCl3)δ:0.93(3H,d,J＝7.4Hz,H-13),0.96(3H,d,J＝7.4Hz,H-14),1.44(3H,s,H-15),1.37-2.12(12H,m,H-2,H-3,H-7～H-10 and H-17),2.21(3H,s,H-21),2.29(3H,s,H-22),2.39(1H,m,H-1),2.61-2.68(1H,m,H-11),3.36-3.41(1H,m,H-16),3.85-3.90(1H,m,H-16),4.03(2H,t,J＝7.1Hz,H-18),4.80(1H,d,J＝2.4Hz,H-12),5.45(1H,s,H-5),5.77(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:147.18(C-21 and C-23),138.39(C-20),104.77(C-4),103.98(C-20),101.79(C-12),87.81(C-5),80.97(C-6),65.07(C-16),52.44(C-1),45.56(C-17),44.30(C-7),37.30(C-11),36.31(C-10),34.54(C-3),30.79(C-9),30.53(C-18),26.07(C-8),24.59(C-15),24.43(C-2),20.27(C-14),13.39(C-13),13.02(C-13),10.85(C-22 and C-23).HR MS:C23H36N2O5[M+Na]+计算值443.2516,测定值443.2518.
3b-6:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.87(3H,d,J＝6.9Hz,H-13),0.98(3H,d,J＝7.5Hz,H-14),1.44(3H,s,H-15),1.26-2.16(12H,m,H-2,H-3,H-7～H-10 and H-17),2.33-2.43(1H,m,H-1),2.68-2.71(1H,m,H-11),3.39-3.47(1H,m,H-16),3.88-3.95(1H,m,H-16),4.30(2H,t,J＝7.2Hz,H-18),4.82(1H,d,J＝2.4Hz,H-12),5.40(1H,s,H-5),7.30-7.33(2H,m,H-22 and H-23),7.41(1H,d,J＝4.8Hz,H-21),7.82-7.85(1H,m,H-24),7.98(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:129.1(C-21 and C-24),116.1(C-22 and C-23),104.0(C-4),102.0(C-12),87.8(C-5),81.0(C-6),66.4(C-16),52.5(C-1),49.0(C-18),44.0(C-7),37.5(C-11),36.4(C-10),34.6(C-3),30.7(C-9),29.7(C-17),26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HRMS:C25H34N2O5[M+H]+计算值443.2541,测定值443.2538.
4a-1:m.p.:100.8-102.4℃； 1H NMR(300MHz,CDCl3)δ:0.74(3H,d,J＝7.2Hz,H-14),0.93(3H,d,J＝5.4Hz,H-13),1.42(3H,s,H-15),1.12-2.11(10H,m,H-2,H-3,H-7～H-10),2.34(1H,m,H-1),2.47-2.63(1H,m,H-11),3.89-3.96(1H,m,H-16),4.33-4.40(1H,m,H-16),4.64(2H,m,H-17),4.77(1H,s,H-12),5.21(1H,s,H-5),7.60(2H,s,H-18)；13C NMR(75MHz,CDCl3)δ:133.96(C-18),103.97(C-4),102.10(C-12),87.79(C-5),80.92(C-6),66.12(C-16),54.73(C-17),52.37(C-1),44.12(C-7),37.13(C-11),36.29(C-10),34.47(C-3),30.58(C-9),26.08(C-8),24.58(C-15),23.93(C-2),20.31(C-14),12.67(C-13).HR MS:C19H29N3O5[M+Na]+计算值402.1999,测定值402.1997.
4a-2:m.p.:128.4-129.7℃； 1H NMR(300MHz,CDCl3)δ:0.81(3H,d,J＝7.2Hz,H-14),0.95(3H,d,J＝5.4Hz,H-13),1.42(3H,s,H-15),1.16-2.08(10H,m,H-2,H-3,H-7～H-10),2.35(1H,m,H-1),2.56-2.65(1H,m,H-11),3.77-3.84(1H,m,H-16),4.26-4.33(1H,m,H-16),4.52-4.60(1H,m,H-17),4.63-4.72(1H,m,H-17),4.78(1H,d,J＝3.2Hz,H-12),5.16(1H,s,H-5),7.62(1H,s,H-18),7.72(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:133.62(C-19),123.94(C-18),104.11(C-4),102.06(C-12),87.77(C-5),80.78(C-6),66.46(C-16),52.33(C-1),50.12(C-17),43.97(C-7),37.18(C-11),36.23(C-10),34.35(C-3),30.54(C-9),26.04(C-8),24.51(C-15),24.19(C-2),20.30(C-14),12.80(C-13).HR MS:C19H29N3O5[M+Na]+计算值402.1999,测定值402.1993.
4a-3:m.p.:93.5-95.2℃； 1H NMR(300MHz,CDCl3)δ:0.78(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.5Hz,H-13),1.42(3H,s,H-15),1.19-2.08(10H,m,H-2,H-3,H-7～H-10),2.31-2.39(1H,m,H-1),2.58-2.62(1H,m,H-11),3.74-3.81(1H,m,H-16),4.09-4.17(1H,m,H-16),4.36-4.38(2H,m,H-17),4.78(1H,s,H-12),5.17(1H,s,H-5),7.96(1H,s,H-19),8.12(1H,s,H-18).
4a-4:m.p.:100.5～104.3℃； 1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.4Hz,H-14),0.96(3H,d,J＝5.6Hz,H-13),1.44(3H,s,H-15),1.27-2.10(10H,m,H-2,H-3,H-7～H-10),2.37(1H,td,J＝14.2,3.7Hz,H-1),2.63-2.74(1H,m,H-11),3.61-3.70(1H,m,H-16),4.08-4.23(3H,m,H-16 and H-17),4.81(1H,d,J＝3.5Hz,H-12),5.27(1H,s,H-5),7.80(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:154.04,140.14,104.17,102.24,87.74,80.72,66.47,52.25,43.91,43.51,37.23,36.18,34.25,30.49,25.95,24.47,24.40,20.21,12.83.HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2105.
4a-5:m.p.:97.3-98.5℃； 1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.4Hz,H-14),0.94(3H,d,J＝6.3Hz,H-13),1.41(3H,s,H-15),1.21-2.09(10H,m,H-2,H-3,H-7～H-10),2.37(1H,td,J＝14.1,3.6Hz,H-1),2.54-2.69(1H,m,H-11),3.23(2H,t,J＝5.8Hz,H-17),3.82-3.66(1H,m,H-16),3.98-4.06(1H,m,H-16),4.83(1H,d,J＝3.2Hz,H-12),5.06(2H,s,H-20),5.57(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:163.32,148.19,104.35,101.96,88.16,81.26,67.28,52.40,44.26,37.28,36.30,34.52,32.05,30.87,25.94,24.52,24.33,20.33,12.93.HR MS:C19H30N4O5S[M-H]-计算值425.1864,测定值425.1866.
4a-6:m.p.:139.3-140.5℃； 1H NMR(300MHz,CDCl3)δ:0.63(3H,d,J＝7.5Hz,H-13),0.85(3H,d,J＝6.0Hz,H-14),1.39(3H,s,H-15),0.97-1.99(10H,m,H-2,H-3,H-7～H-10),2.23-2.34(1H,m,H-1),2.47-2.50(1H,m,H-11),3.88-3.93(1H,m,H-16),4.45-4.52(1H,m,H-16),4.73(1H,d,J＝3.0Hz,H-12),4.80-4.93(3H,m,H-5 and H-17),7.37(1H,t,J＝7.5Hz,H-21),7.49(1H,t,J＝7.2Hz,H-20),7.57(1H,d,J＝8.1Hz,H-19),7.86(2H,d,J＝8.4Hz,H-22)；13C NMR(75MHz,CDCl3)δ:145.8(C-23),133.5(C-18),127.1(C-21),123.8(C-20),119.8(C-22),109.6(C-19),104.0(C-4),102.0(C-12),87.6(C-5),80.7(C-6),66.1(C-16),52.2(C-1),48.0(C-17),43.9(C-7),36.9(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.4(C-15),24.0(C-2),20.2(C-14),12.6(C-13).HR MS:C23H31N3O5[M+Na]+计算值452.2156,测定值452.2151.
4a-7:m.p.:65.6-67.3℃； 1H NMR(300MHz,CDCl3)δ:0.73(3H,d,J＝6.9Hz,H-13),0.87(3H,d,J＝7.5Hz,H-14),1.42(3H,s,H-15),1.01-1.99(10H,m,H-2,H-3,H-7～H-10),2.25-2.33(1H,m,H-1),2.49-2.55(1H,m,H-11),4.00-4.04(1H,m,H-16),4.62-4.68(1H,m,H-16),4.81(1H,s,H-12),4.89-5.03(3H,m,H-5and H-17),7.38(1H,d,J＝9.0Hz,H-20),7.86(2H,d,J＝9.3Hz,H-19)；13C NMR(75MHz,CDCl3)δ:143.5(C-18),126.2(C-20),117.9(C-19),103.9(C-4),101.7(C-12),87.7(C-5),80.8(C-6),65.5(C-16),56.5(C-17),52.2(C-1),44.0(C-7),36.7(C-11),36.3(C-10),34.3(C-3),30.6(C-9),26.1(C-8),24.5(C-15),23.9(C-2),20.1(C-14),12.7(C-13).HRMS:C23H31N3O5[M+Na]+计算值452.2156,测定值452.2159.
4a-8:m.p.:131.2-132.7℃； 1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.2Hz,H-14),0.95(3H,d,J＝6.0Hz,H-13),1.44(3H,s,H-15),1.26-2.06(10H,m,H-2,H-3,H-7～H-10),2.32-2.43(H,m,H-1),2.65-2.72(H,m,H-11),3.83～3.90(1H,m,H-16),4.22-4.29(1H,m,H-16),4.75(2H,t,J＝3.6Hz,H-17),4.87(1H,s,H-12),5.45(1H,s,H-5),7.40(1H,t,J＝7.5Hz,H-21),7.52(1H,t,J＝7.5Hz,H-20),7.62(1H,d,J＝8.4Hz,H-22),8.03(1H,d,J＝8.4Hz,H-19)；13C NMR(75MHz,CDCl3)δ:143.5(C-23),127.9(C-18),127.4(C-19),124.6(C-21),120.3(C-20),108.6(C-22),104.1(C-4),102.3(C-12),88.0(C-5),81.0(C-6),79.7(C-17),65.5(C-16),52.5(C-1),44.3(C-7),37.3(C-11),36.3(C-10),34.5(C-3),30.7(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),12.9(C-13).HR MS:C23H31N3O6[M+Na]+计算值468.2105,测定值468.2098.
4b-1:m.p.:100.8-102.4℃； 1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.2Hz,H-14).,0.96(3H,d,J＝6.2Hz,H-13),1.43(3H,s,H-15),1.17-2.10(10H,m,H-2,H-3,H-7～H-10),2.16-2.28(2H,m,H-17),2.37(1H,m,H-1),2.56-2.72(1H,m,H-11),3.26-3.43(1H,m,H-16),3.81-3.88(1H,m,H-16),4.54(2H,m,H-18),4.79(1H,d,J＝3.2Hz,H-12),5.44(1H,s,H-5),7.59(2H,s,H-18)；13C NMR(75MHz,CDCl3)δ:133.98(C-19),104.00(C-4),102.09(C-12),87.85(C-5),81.05(C-6),64.78(C-16),52.51(C-17),51.86(C-1),44.34(C-7),37.29(C-11),36.36(C-10),34.59(C-3),30.84(C-9),29.88(C-18),26.15(C-8),24.64(C-15),24.43(C-2),20.35(C-14),13.01(C-13).HR MS:C20H31N3O5[M+Na]+计算值416.2156,测定值416.2155.
4b-2:m.p.:100.8-102.4℃； 1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.2Hz,H-14),0.96(3H,d,J＝6.1Hz,H-13),1.43(3H,s,H-15),1.21-2.25(12H,m,H-2,H-3,H-7～H-10 and H-17),2.28-2.43(1H,m,H-1),2.65(1H,m,H-11),3.31-3.43(1H,m,H-16),3.83-3.94(1H,m,H-16),4.46-4.52(2H,m,H-17),4.78(1H,d,J＝3.2Hz,H-12),5.40(1H,s,H-5),7.56(1H,s,H-18),7.72(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:133.77(C-20),123.48(C-19),104.10(C-4),102.04(C-12),87.84(C-5),80.94(C-6),64.52(C-16),52.41(C-1),47.19(C-17),44.18(C-7),37.34(C-11),36.27(C-10),34.46(C-3),30.75(C-9),30.41(C-18),26.08(C-8),24.56(C-15),24.45(C-2),20.31(C-14),13.04(C-13).HR MS:C20H31N3O5[M+Na]+计算值416.2156,测定值416.2157.
4b-3:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.92-0.97(6H,m,H-14 and H-13),1.43(3H,s,H-15),1.19-2.08(10H,m,H-2,H-3,H-7～H-10),2.16-2.19(2H,m,H-17),2.32-2.36(1H,m,H-1),2.64-2.67(1H,m,H-11),3.32-3.40(1H,m,H-16),3.84-3.91(1H,m,H-16),4.28(2H,t,J＝6.9Hz,H-18),4.77(1H,s,H-12),5.39(1H,s,H-5),7.96(1H,s,H-20),8.09(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:151.9(C-20),143.0(19),104.1(C-4),102.0(C-12),87.8(C-5),80.9(C-6),64.5(C-16),52.4(C-1),46.7(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),29.9(C-18),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H31N3O5[M+Na]+计算值416.2156,测定值416.2155.
4b-4:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.4Hz,H-14),0.96(3H,d,J＝5.1Hz,H-13),1.43(3H,s,H-15),1.25-2.15(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37(1H,td,J＝14.0,3.8Hz,H-1),2.62-2.71(1H,m,H-11),3.55-3.62(1H,m,H-16),3.84-3.92(1H,m,H-16),3.97-4.08(2H,m,H-18),4.81(1H,d,J＝3.3Hz,H-12),5.44(1H,s,H-5),7.65(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:153.99,142.09,104.21,101.97,87.84,80.88,64.67,52.43,46.28,44.22,37.41,36.26,34.45,30.77,29.32,26.04,24.59,24.46,20.28,13.06.HR MS:C20H32N4O5[M+Na]+计算值431.2265,测定值431.2266.
4b-5:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.4Hz,H-14),0.94(3H,d,J＝6.3Hz,H-13),1.41(3H,s,H-15),1.21-2.09(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37(1H,td,J＝14.1,3.6Hz,H-1),2.54-2.69(1H,m,H-11),3.23(2H,t,J＝5.8Hz,H-18),3.66-3.82(1H,m,H-16),3.98-4.06(1H,m,H-16),4.80(1H,d,J＝3.2Hz,H-12),5.44(2H,s,H-21),5.57(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:163.55,148.20,104.21,101.97,87.93,80.93,64.67,52.43,44.22,37.40,36.31,34.50,30.87,29.65,26.11,24.59,24.46,20.31,13.06.HR MS:C20H32N4O5S[M+Na]+计算值463.1986,测定值463.1986.
4b-6:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.5Hz,H-13),0.97(3H,d,J＝6.9Hz,H-14),1.42(3H,s,H-15),1.21-2.06(10H,m,H-2,H-3,H-7～H-10),2.31-2.44(3H,m,H-1 and H-17),2.60-2.70(1H,m,H-11),3.37-3.45(1H,m,H-16),3.86-3.93(1H,m,H-16),4.79-4.87(3H,m,H-12 and H-18),5.50(1H,s,H-5),7.37-7.41(2H,m,H-21),7.84-7.88(2H,m,H-20)；13C NMR(75MHz,CDCl3)δ:144.3(C-19),126.3(C-21),117.9(C-20),104.0(C-4),102.1(C-12),87.9(C-5),81.1(C-6),64.8(C-16),53.7(C-18),52.6(C-1),44.4(C-7),37.3(C-11),36.4(C-10),34.6(C-3),30.7(C-9),26.2(C-8),24.7(C-15),24.5(C-2),22.7(C-17),20.4(C-14),13.0(C-13).HRMS:C24H33N3O5[M+Na]+计算值466.2312,测定值466.2309.
4b-7:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.95-0.98(6H,m,H-13 and H-14),1.43(3H,s,H-15),1.26-2.09(10H,m,H-2,H-3,H-7～H-10),2.28-2.42(3H,m,H-1 and H-17),2.65-2.70(1H,m,H-11),3.41-3.48(1H,m,H-16),3.88-3.95(1H,m,H-16),4.72-4.78(2H,m,H-18),4.81(1H,d,J＝3.3Hz,H-12),5.44(3H,s,H-5),7.38(1H,t,J＝7.5Hz,H-21),7.46-7.55(2H,m,H-22 and H-23),8.08(1H,d,J＝7.8Hz,H-20)；13C NMR(75MHz,CDCl3)δ:145.9(C-19),133.0(C-24),127.3(C-21),123.9(C-22),120.0(C-20),109.2(C-23),104.2(C-4),102.1(C-12),87.9(C-5),81.0(C-6),64.8(C-16),52.5(C-1),45.3(C-18),44.3(C-7),37.4(C-11),36.3(C-10),34.6(C-3),30.6(C-9),29.9(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:C24H33N3O5[M+Na]+计算值466.2312,测定值466.2310.
4b-8:m.p.:106.3-108.1℃； 1H NMR(300MHz,CDCl3)δ:0.88(3H,d,J＝9.3Hz,H-14),0.93(3H,d,J＝7.2Hz,H-13),1.45(3H,s,H-15),1.22-2.03(10H,m,H-2,H-3,H-7～H-10),2.13-2.17(2H,m,H-17),2.32-2.42(H,m,H-1),2.64-2.71(H,m,H-11),3.62-3.67(1H,m,H-16),4.10～4.18(1H,m,H-16),4.66(2H,t,J＝6.0Hz,H-18),4.85(1H,s,H-12),5.43(1H,s,H-5),7.40(1H,t,J＝7.2Hz,H-21),7.52(1H,t,J＝7.2Hz,H-22),7.59(1H,d,J＝7.8Hz,H-23),8.02(1H,d,J＝8.7Hz,H-20)；13C NMR(75MHz,CDCl3)δ:143.5(C-24),127.9(C-19),127.3(C-20),124.5(C-22),120.3(C-21),108.5(C-23),104.1(C-4),102.1(C-12),87.9(C-5),81.0(C-6),77.4(C-18),64.1(C-16),52.5(C-1),44.3(C-7),37.3(C-11),36.4(C-10),34.5(C-3),30.8(C-9),28.6(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C24H33N3O6[M+Na]+计算值482.2262,测定值482.2260.
5a-1:m.p.:135.2-136.5℃； 1H NMR(300MHz,CDCl3)δ:0.72(3H,d,J＝7.8Hz,H-13),0.95(3H,d,J＝5.1Hz,H-14),1.43(3H,s,H-15),1.25-2.06(10H,m,H-2,H-3,H-7～H-10),2.31-2.40(1H,m,H-1),2.63-2.65(1H,m,H-11),3.80-3.86(1H,m,H-16),4.28-4.35(1H,m,H-16),4.63(2H,t,J＝4.8Hz,H-18),4.79(1H,s,H-12),5.19(1H,s,H-5),8.64(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:143.0(C-18),104.2(C-4),102.3(C-12),87.9(C-5),80.7(C-6),65.7(C-16),52.3(C-1),48.4(C-17),43.9(C-7),37.3(C-11),36.3(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.3(C-2),20.3(C-14),12.8(C-13).HR MS:C18H28N4O5[M+Na]+计算值403.1952,测定值403.1951.
5a-2:m.p.:123.2-124.6℃； 1H NMR(300MHz,CDCl3)δ:0.72(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝4.8Hz,H-14),1.43(3H,s,H-15),1.24-2.05(10H,m,H-2,H-3,H-7～H-10),2.31-2.39(1H,m,H-1),2.54-2.61(1H,m,H-11),3.96-4.03(1H,m,H-16),4.38-4.45(1H,m,H-16),4.78(1H,s,H-12),4.87(2H,t,J＝4.8Hz,H-17),5.22(1H,s,H-5),8.52(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:152.8(C-18),104.1(C-4),102.2(C-12),87.9(C-5),80.9(C-6),65.5(C-16),53.1(C-17),52.4(C-1),44.1(C-7),37.3(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.0(C-2),20.3(C-14),12.6(C-13).HR MS:C18H28N4O5[M+Na]+计算值403.1952,测定值403.1949.
5a-3:m.p.:117.4-119.1℃； 1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝5.7Hz,H-13),1.43(3H,s,H-15),1.26-2.07(10H,m,H-2,H-3,H-7～H-10),2.32-2.42(1H,m,H-1),2.56(1H,s,H-20),2.62-2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-4.38(2H,m,H-18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75,103.96,102.03,87.79,80.89,64.22,52.46,49.83,44.24,37.22,36.29,34.53,30.73,26.03,24.58,24.39,20.27,12.90,10.76.HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2106.
5a-4:m.p.:114.2-115.7℃； 1H NMR(300MHz,CDCl3)δ:0.75(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.5Hz,H-13),1.42(3H,s,H-15),1.21-2.04(10H,m,H-2,H-3,H-7～H-10),2.29-2.38(1H,m,H-1),2.57(3H,s,H-19),2.58-2.61(1H,m,H-11),3.80-3.87(1H,m,H-16),4.34-4.37(1H,m,H-16),4.46-4.48(2H,m,H-17),4.76(1H,s,H-12),5.11(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:152.1(C-18),104.2(C-4),102.3(C-12),87.7(C-5),80.7(C-6),65.8(C-16),52.3(C-1),47.0(C-17),43.9(C-7),37.2(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.2(C-2),20.3(C-14),13.0(C-13),8.9(C-19).HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2106.
5a-5:m.p.:121.7-123.3℃； 1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-14),0.96(3H,d,J＝6.3Hz,H-13),1.43(3H,s,H-15),1.21-2.04(10H,m,H-2,H-3,H-7～H-10),2.32-2.43(H,m,H-1),2.61-2.66(H,m,H-11),3.63(2H,t,J＝5.7Hz,H-17),3.75-3.83(1H,m,H-16),3.93(3H,s,H-19),4.12-4.19(H,m,H-16),4.83(1H,d,J＝2.7Hz,H-12),5.43(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.0(C-18),104.1(C-4),102.2(C-12),87.9(C-5),80.9(C-6),66.5(C-16),52.4(C-1),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),33.6(C-17),33.4(C-19),30.7(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),12.9(C-13).HR MS:C19H30N4O5S[M+Na]+计算值449.1829,测定值449.1821.
5a-6:m.p.:129.8-130.8℃； 1H NMR(300MHz,CDCl3)δ:0.87(3H,d,J＝6.9Hz,H-13),0.98(3H,d,J＝7.5Hz,H-14),1.44(3H,s,H-15),1.26-2.12(10H,m,H-2,H-3,H-7～H-10),2.33-2.43(1H,m,H-1),2.68-2.71(1H,m,H-11),3.94-4.00(1H,m,H-16),4.52-4.59(1H,m,H-16),4.78-4.82(1H,m,H-17),4.83(1H,d,J＝2.7Hz,H-12),4.91-4.99(1H,m,H-17),5.15(1H,s,H-5),7.47-7.50(3H,m,H-21 and H-22),8.17(1H,d,J＝5.4Hz,H-20)；13C NMR(75MHz,CDCl3)δ:165.1(C-18),130.3(C-22),128.8(C-21),127.3(C-19),126.7(C-20),104.0(C-4),102.0(C-12),87.8(C-5),80.8(C-6),64.9(C-16),52.1(C-1),52.3(C-17),44.0(C-7),37.1(C-11),36.3(C-10),34.2(C-3),30.6(C-9),26.1(C-8),24.4(C-15),24.0(C-2),20.0(C-14),12.87(C-13).HR MS:C24H32N4O5[M+Na]+计算值479.2265,测定值479.2268.
5b-1:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.8Hz,H-13),0.97(3H,d,J＝6.6Hz,H-14),1.44(3H,s,H-15),1.26-2.06(10H,m,H-2,H-3,H-7～H-10),2.22-2.28(2H,m,H-17),2.33-2.42(1H,m,H-1),2.63-2.70(1H,m,H-11),3.39-3.46(1H,m,H-16),3.87-3.94(1H,m,H-16),4.54(2H,t,J＝6.9Hz,H-18),4.79(H,s,H-12),5.39(1H,s,H-5),8.62(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:142.6(C-19),104.2(C-4),102.2(C-12),87.9(C-5),80.9(C-6),64.3(C-16),52.4(C-1),45.5(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),30.0(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2111.
5b-2:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.93-0.98(6H,m,H-13 and H-14),1.43(3H,s,H-15),1.26-2.06(10H,m,H-2,H-3,H-7～H-10),2.28-2.32(2H,m,H-17),2.37-2.43(1H,m,H-1),2.61-2.68(1H,m,H-11),3.35-3.42(1H,m,H-16),3.86-3.92(1H,m,H-16),4.74-4.79(3H,m,H-12 and H-18),5.41(1H,s,H-5),8.51(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:152.8(C-19),104.1(C-4),102.2(C-12),87.9(C-5),81.0(C-6),64.4(C-16),52.5(C-1),50.2(C-18),44.3(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),29.5(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2114.
5b-3:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝5.7Hz,H-13),1.43(3H,s,H-15),1.26-2.07(10H,m,H-2,H-3,H-7～H-10),2.16-2.22(2H,m,H-17),2.32-2.42(1H,m,H-1),2.56(1H,s,H-20),2.62-2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-4.38(2H,m,H-18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75(C-19),103.96(C-4),102.03(C-12),87.79(C-5),80.89(C-6),64.22(C-16),52.46(C-1),49.83(C-18),44.24(C-7),37.22(C-11),36.29(C-10),34.53(C-3),30.73(C-9),29.38(C-17),26.03(C-8),24.58(C-15),24.39(C-2),20.27(C-14),12.90(C-13),10.76(C-20).HRMS:C20H32N4O5[M+Na]+计算值431.2265,测定值431.2272.
5b-4:黄色油状物； 1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.5Hz,H-13),0.97(3H,d,J＝6.1Hz,H-13),1.44(3H,s,H-15),1.19-2.10(10H,m,H-2,H-3,H-7～H-10),2.14-2.27(2H,m,H-17),2.32-2.47(1H,m,H-1),2.57(3H,s,H-20),2.64-2.73(1H,m,H-11),3.39-3.59(1H,m,H-16),3.88-3.95(1H,m,H-16),4.33-4.43(2H,m,H-18),4.81(1H,d,J＝3.3Hz,H-12),5.41(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.16(C-4),102.01(C-12),87.87(C-5),80.86(C-6),64.31(C-16),52.42(C-1),44.27(C-18),44.17(C-7),37.41(C-11),36.30(C-10),34.48(C-3),30.71(C-9),29.72(C-17),26.04(C-8),24.59(C-15),24.48(C-2),20.26(C-14),12.99(C-13),8.70(C-20).HR MS:C20H32N4O5[M+Na]+计算值431.2265,测定值431.2273.
5b-5:黄色浆状物； 1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝6.3Hz,H-13),1.43(3H,s,H-15),1.25-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.32-2.41(1H,m,H-1),2.62-2.67(1H,m,H-11),3.42-3.55(3H,m,H-16 and H-18),3.92(1H,s,H-20),3.97-4.04(1H,m,H-16),4.80(1H,d,J＝3.0Hz,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.2(C-19),104.1(C-4),102.1(C-12),87.9(C-5),81.0(C-6),66.0(C-16),52.4(C-1),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),33.3(C-18),30.8(C-9),30.3(C-17),29.1(C-20),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H32N4O5S[M+Na]+计算值463.1986,测定值463.1985.
5b-6:白色浆状物； 1H NMR(300MHz,CDCl3)δ:0.87(3H,d,J＝7.2Hz,H-13).0.96(3H,d,J＝6.7Hz,H-14),1.43(3H,s,H-15),1.12-2.11(10H,m,H-2,H-3,H-7～H-10),2.31-2.37(3H,m,H-1,H-17),2.62-2.72(1H,m,H-11),3.36-3.54(1H,m,H-16),3.97-4.01(1H,m,H-16),4.73-4.81(2H,m,H-18),4.82(1H,d,J＝2.7Hz,H-12),5.46(1H,s,H-5),7.42-7.58(3H,m,H-22 and H-23),8.27-8.07(2H,d,J＝5.4Hz,H-21)；13C NMR(75MHz,CDCl3)δ:165.11(C-19),130.21(C-23),128.80(C-22),127.40(C-20),126.81(C-21),104.07(C-4),102.21(C-12),87.87(C-5),80.98(C-6),64.51(C-16),52.52(C-1),50.28(C-17),44.31(C-7),37.37(C-11),36.37(C-10),34.55(C-3),30.82(C-9),29.67(C-18),26.12(C-8),24.61(C-15),24.53(C-2),20.31(C-14),12.99(C-13).HR MS:C25H34N4O5[M+Na]+计算值493.2427,测定值493.2421.
实施例3、DHA胺类衍生物和DHA唑类衍生物的抗血管生成活性测试
DHA胺类衍生物和DHA唑类衍生物的抗血管生成活性委托美国礼来公司OpenInnovation Drug Discovery(OIDD)program进行测试，首先进行单浓度初筛(PrimarySP)，然后对初步筛选出的潜力分子进行多浓度测试(Primary CRC)。结果见表5。
表5抗血管生成活性测试结果
从表5可以看出,目标化合物1～5大部分具有一定的抗血管生成活性，其中7个化合物(1c,2a-4,2a-5,2b-1,4b-6,4b-8和5b-6)在10μM测试浓度下的抑制活性大于50％，化合物2b-1的抑制活性最高达到了94％；在2μM测试浓度下，化合物1c,2b-1,4b-6,4b-8,5b-6的抑制率同样接近或超过50％；特别地，从抗血管生成IC50值看，化合物2b-1,4b-8,5b-6均在2μM及以下。整体来看，DHA胺类和唑类衍生物表现出了很强的抗血管生成活性，可作为抗血管生成药物进一步开发。
最后说明的是，以上优选实施例仅用以说明本发明的技术方案而非限制，尽管通过上述优选实施例已经对本发明进行了详细的描述，但本领域技术人员应当理解，可以在形式上和细节上对其作出各种各样的改变，而不偏离本发明权利要求书所限定的范围。
Claims (6)
1.式I所示的二氢青蒿素衍生物或其消旋体、立体异构体、互变异构体、氮氧化物、药学上可接受的盐在制备抗血管生成药物中的应用：
式I中，n为1或2；
Y为-NR1R2、
R1和R2独立地为H、C1-C3烷基或C1-C3羟烷基；
R3为H、C1-C3烷基、C1-C3羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或脂肪酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基；
R4和R5独立地为H或C1-C3烷基；
R6和R7独立地为H、氨基、羟基或C1-C3烷基；
R8为H、C1-C3烷基、C1-C3烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基。
2.如权利要求1所述的应用，其特征在于：式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或烷酰基；
所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基。
3.如权利要求2所述的应用，其特征在于：式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、苯基、叔丁氧羰基、苄氧羰基或乙酰基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基或苯基。
4.如权利要求3所述的应用，其特征在于：式I中，
R1和R2独立地为H、甲基、乙基或羟乙基；
R3为H、甲基、羟乙基、苯基或叔丁氧羰基；
R4和R5独立地为H或甲基；
R6和R7独立地为H或氨基；
R8为H、甲基、甲硫基或苯基。
5.如权利要求4所述的应用，其特征在于：式I所示的二氢青蒿素衍生物为以下化合物中的任一种：
6.如权利要求5所述的应用，其特征在于：式I所示的二氢青蒿素衍生物为以下化合物中的任一种：1c,2a-4,2a-5,2b-1,4b-6,4b-8,5b-6。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910785570.9A CN110448551A (zh) | 2019-08-23 | 2019-08-23 | 二氢青蒿素衍生物在制备抗血管生成药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910785570.9A CN110448551A (zh) | 2019-08-23 | 2019-08-23 | 二氢青蒿素衍生物在制备抗血管生成药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110448551A true CN110448551A (zh) | 2019-11-15 |
Family
ID=68488892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910785570.9A Pending CN110448551A (zh) | 2019-08-23 | 2019-08-23 | 二氢青蒿素衍生物在制备抗血管生成药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110448551A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
| CN114933603A (zh) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | 一种青蒿素的衍生物及其制备方法与应用 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296009A (zh) * | 1999-11-12 | 2001-05-23 | 中国科学院上海药物研究所 | 含氮杂环基的青蒿素衍生物及其制备方法 |
| CN1448138A (zh) * | 2003-04-29 | 2003-10-15 | 浙江大学 | 青蒿琥酯和二氢青蒿素抗血管生成作用的药物制剂及用途 |
| US20040072896A1 (en) * | 2002-10-15 | 2004-04-15 | Elsohly Mahmoud A. | Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| CN101879158A (zh) * | 2010-07-01 | 2010-11-10 | 中国科学院广州生物医药与健康研究院 | 青蒿素衍生物的新应用 |
| CN102010422A (zh) * | 2010-11-23 | 2011-04-13 | 沈阳药科大学 | 含有胍基的青蒿素类衍生物及其应用 |
| CA2807263A1 (en) * | 2010-08-03 | 2012-02-09 | Dafra Pharma N.V. | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
| CN102675337A (zh) * | 2012-05-21 | 2012-09-19 | 中国人民解放军第三军医大学 | 二氢青蒿素衍生物及其应用 |
| CN103183682A (zh) * | 2011-12-31 | 2013-07-03 | 沈阳药科大学 | C-10位脲基取代的青蒿素衍生物及其制备方法和用途 |
| CN104974171A (zh) * | 2015-05-28 | 2015-10-14 | 沈阳药科大学 | 二氢青蒿素苯基醚衍生物及其应用 |
| CN105503898A (zh) * | 2015-11-16 | 2016-04-20 | 中国人民解放军第三军医大学 | 一种含氮杂环的青蒿素衍生物及其制备方法 |
-
2019
- 2019-08-23 CN CN201910785570.9A patent/CN110448551A/zh active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296009A (zh) * | 1999-11-12 | 2001-05-23 | 中国科学院上海药物研究所 | 含氮杂环基的青蒿素衍生物及其制备方法 |
| US20040072896A1 (en) * | 2002-10-15 | 2004-04-15 | Elsohly Mahmoud A. | Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| CN1448138A (zh) * | 2003-04-29 | 2003-10-15 | 浙江大学 | 青蒿琥酯和二氢青蒿素抗血管生成作用的药物制剂及用途 |
| CN101879158A (zh) * | 2010-07-01 | 2010-11-10 | 中国科学院广州生物医药与健康研究院 | 青蒿素衍生物的新应用 |
| CA2807263A1 (en) * | 2010-08-03 | 2012-02-09 | Dafra Pharma N.V. | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
| CN102010422A (zh) * | 2010-11-23 | 2011-04-13 | 沈阳药科大学 | 含有胍基的青蒿素类衍生物及其应用 |
| CN103183682A (zh) * | 2011-12-31 | 2013-07-03 | 沈阳药科大学 | C-10位脲基取代的青蒿素衍生物及其制备方法和用途 |
| CN102675337A (zh) * | 2012-05-21 | 2012-09-19 | 中国人民解放军第三军医大学 | 二氢青蒿素衍生物及其应用 |
| CN104974171A (zh) * | 2015-05-28 | 2015-10-14 | 沈阳药科大学 | 二氢青蒿素苯基醚衍生物及其应用 |
| CN105503898A (zh) * | 2015-11-16 | 2016-04-20 | 中国人民解放军第三军医大学 | 一种含氮杂环的青蒿素衍生物及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| CHONG WU，等: "Design, Synthesis and Evaluation of the Antibacterial Enhancement Activities of Amino Dihydroartemisinin Derivatives", 《MOLECULES》, vol. 18, 31 December 2013 (2013-12-31), pages 6869 * |
| MORAKE, MOKHITLI，等: "Preliminary Evaluation of Artemisinin-Cholesterol Conjugates as Potential Drugs for the Treatment of Intractable Forms of Malaria and Tuberculosis", 《CHEMMEDCHEM》, vol. 13, no. 1, 31 January 2018 (2018-01-31), pages 4, XP055753068, DOI: 10.1002/cmdc.201700579 * |
| SOOMRO, SHAHID，等: "Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties", 《JOURNAL OF CELLULAR AND MOLECULAR MEDICINE》, vol. 15, no. 5, 31 May 2011 (2011-05-31), pages 1123 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
| CN114933603A (zh) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | 一种青蒿素的衍生物及其制备方法与应用 |
| WO2023236485A1 (zh) * | 2022-06-10 | 2023-12-14 | 上海英诺富成生物科技有限公司 | 一种青蒿素的衍生物及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110448552B (zh) | 二氢青蒿素衍生物在制备抗疟药物中的应用 | |
| RU2682672C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| BR112018067392A2 (pt) | inibidores de ligação entre proteínas wdr5 | |
| RU2762968C2 (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| WO2020163823A2 (en) | Therapeutic agents and methods of treatment | |
| BR112015023142B1 (pt) | Moduladores do p2x7, seu uso, processo de preparação e composição farmacêutica que os compreende | |
| CN112125911B (zh) | Cdk9抑制剂及其制备方法与应用 | |
| CN110448551A (zh) | 二氢青蒿素衍生物在制备抗血管生成药物中的应用 | |
| WO2016100578A2 (en) | Antimicrobial polymyxins for treatment of bacterial infections | |
| EP4090658A1 (en) | Therapeutic agents and methods of treatment | |
| CA3097949A1 (en) | Hpk1 inhibitors, preparation method and application thereof | |
| CA3207392A1 (en) | Cdk inhibitor | |
| CA2959747C (en) | Compounds as crth2 antagonist and uses thereof | |
| CN110403933A (zh) | 二氢青蒿素衍生物在制备抗肿瘤药物中的应用 | |
| CN110496121A (zh) | 二氢青蒿素衍生物在制备抗利什曼原虫的药物中的应用 | |
| KR20240073982A (ko) | 암 치료를 위한 소분자 | |
| KR20120089437A (ko) | 플라빈 유도체 | |
| CN110368383A (zh) | 二氢青蒿素衍生物在制备降血脂药物中的应用 | |
| CN113754680A (zh) | 一种α氟代酰基哌嗪衍生物及其制备和应用 | |
| EP3083624B1 (en) | Tetrahydro-tetrazolo[1,5-a]pyrazines as ror-gamma inhibitors | |
| CA3210658A1 (en) | Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis | |
| CN103396400B (zh) | 含吡唑酰胺类化合物、其制备方法和用途 | |
| KR20230007441A (ko) | 페로포르틴 억제제로서의 시클로알킬 피리미딘 | |
| CA3181583A1 (en) | Methods of use for pyrimidines as ferroportin inhibitors | |
| LV15558B (lv) | Selenofēnhromēnfosfonskābes, to iegūšana un izmantošana par pretaudzēju aģentiem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191115 |